However, in the same study, it was shown that treatment with rosiglitazone, a commonly utilized PPAR-γ agonist, also resulted in cardiac hypertrophy, in both wild type and cardiac-specific PPAR-γ knockout mice. This evidence concerns the gene PPARG and cardiac hypertrophy.